It's September, they just raised 8m in March, they burnt cash to...

It's September, they just raised 8m in March, they burnt cash to increase staffing levels and despite that ebitda improved. They would have run out of cash without the raise, but without the raise they would not have increased the staffing levels.

one of the primary function of listing a company is to raise capital. They may need to raise capital next year, they may not we will know better at the AGM.

They went many years without raising capital with track and management probably thought 2rt would provide revenue and then swapped tracks to promote track advance, with the poor trial results.

Revenue has been increasing more than expenses and less money is being spent on regulatory issues and more on marketing now so sales should increase, if they do they don't need cash, if they don't they will and then they will probably need rct evidence to get patient to use their device.

omni's trials will give surrogate evidence